BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 22870815)

  • 1. Effects of furanocoumarins in Kampo extract-based medicines on rat intestinal absorption of CYP3A and P-glycoprotein substrate drugs in vivo.
    Iwanaga K; Arimune K; Miyazaki M; Shibano M; Taniguchi M; Baba K; Kakemi M
    Arch Pharm Res; 2012 Jun; 35(6):1055-64. PubMed ID: 22870815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Furanocoumarin derivatives in Kampo extract medicines inhibit cytochrome P450 3A4 and P-glycoprotein.
    Iwanaga K; Hayashi M; Hamahata Y; Miyazaki M; Shibano M; Taniguchi M; Baba K; Kakemi M
    Drug Metab Dispos; 2010 Aug; 38(8):1286-94. PubMed ID: 20463004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants.
    Xiao CQ; Chen R; Lin J; Wang G; Chen Y; Tan ZR; Zhou HH
    Xenobiotica; 2012 Feb; 42(2):173-8. PubMed ID: 21943317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats.
    Zhang W; Tan TM; Lim LY
    Drug Metab Dispos; 2007 Jan; 35(1):110-5. PubMed ID: 17050652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats.
    Hirunpanich V; Murakoso K; Sato H
    Int J Pharm; 2008 Mar; 351(1-2):133-43. PubMed ID: 18082981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone.
    Yumoto R; Murakami T; Sanemasa M; Nasu R; Nagai J; Takano M
    Drug Metab Dispos; 2001 Feb; 29(2):145-51. PubMed ID: 11159804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of short-term and long-term pretreatment of Schisandra lignans on regulating hepatic and intestinal CYP3A in rats.
    Lai L; Hao H; Wang Q; Zheng C; Zhou F; Liu Y; Wang Y; Yu G; Kang A; Peng Y; Wang G; Chen X
    Drug Metab Dispos; 2009 Dec; 37(12):2399-407. PubMed ID: 19741040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pharmacodynamic-pharmacokinetic (PD-PK) study on the effects of Danshen (Salvia miltiorrhiza) on midazolam, a model CYP3A probe substrate, in the rat.
    Wang X; Lee WY; Zhou X; Or PM; Yeung JH
    Phytomedicine; 2010 Sep; 17(11):876-83. PubMed ID: 20637580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro to in vivo evidence of the inhibitor characteristics of Schisandra lignans toward P-glycoprotein.
    Liang Y; Zhou Y; Zhang J; Liu Y; Guan T; Wang Y; Xing L; Rao T; Zhou L; Hao K; Xie L; Wang GJ
    Phytomedicine; 2013 Aug; 20(11):1030-8. PubMed ID: 23731657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model.
    Cummins CL; Salphati L; Reid MJ; Benet LZ
    J Pharmacol Exp Ther; 2003 Apr; 305(1):306-14. PubMed ID: 12649383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circadian variations in exsorptive transport: in situ intestinal perfusion data and in vivo relevance.
    Okyar A; Dressler C; Hanafy A; Baktir G; Lemmer B; Spahn-Langguth H
    Chronobiol Int; 2012 May; 29(4):443-53. PubMed ID: 22489638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo inhibition of CYP3A-mediated midazolam metabolism by anchusan in rats.
    Saito Y; Nishimura Y; Kurata N; Iwase M; Aoki K; Yasuhara H
    J Pharmacol Sci; 2011; 115(3):399-407. PubMed ID: 21358120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys.
    Ogasawara A; Kume T; Kazama E
    Drug Metab Dispos; 2007 Mar; 35(3):410-8. PubMed ID: 17142564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-clinical evidence of enhanced oral bioavailability of the P-glycoprotein substrate talinolol in combination with morin.
    Pathak SM; Udupa N
    Biopharm Drug Dispos; 2010 Mar; 31(2-3):202-14. PubMed ID: 20238375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory effects of furanocoumarin derivatives in Kampo extract medicines on P-glycoprotein at the blood-brain barrier.
    Iwanaga K; Yoneda S; Hamahata Y; Miyazaki M; Shibano M; Taniguchi M; Baba K; Kakemi M
    Biol Pharm Bull; 2011; 34(8):1246-51. PubMed ID: 21804213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants.
    Malati CY; Robertson SM; Hunt JD; Chairez C; Alfaro RM; Kovacs JA; Penzak SR
    J Clin Pharmacol; 2012 Jun; 52(6):932-9. PubMed ID: 21646440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of efavirenz on intestinal p-glycoprotein and hepatic p450 function in rats.
    Berruet N; Sentenac S; Auchere D; Gimenez F; Farinotti R; Fernandez C
    J Pharm Pharm Sci; 2005 Aug; 8(2):226-34. PubMed ID: 16124934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound.
    Spahn-Langguth H; Baktir G; Radschuweit A; Okyar A; Terhaag B; Ader P; Hanafy A; Langguth P
    Int J Clin Pharmacol Ther; 1998 Jan; 36(1):16-24. PubMed ID: 9476144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased oral absorption of cyclosporine A after liver ischemia-reperfusion injury in rats: the contribution of CYP3A and P-glycoprotein to the first-pass metabolism in intestinal epithelial cells.
    Ikemura K; Urano K; Matsuda H; Mizutani H; Iwamoto T; Okuda M
    J Pharmacol Exp Ther; 2009 Jan; 328(1):249-55. PubMed ID: 18842703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An antioxidant Trolox restores decreased oral absorption of cyclosporine A after liver ischemia-reperfusion through distinct mechanisms between CYP3A and P-glycoprotein in the small intestine.
    Ikemura K; Inoue K; Mizutani H; Oka H; Iwamoto T; Okuda M
    Eur J Pharmacol; 2012 Sep; 690(1-3):192-201. PubMed ID: 22749977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.